Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics, Inc. (JSPR)
:JSPR
Holding JSPR?
Track your performance easily
JSPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.85 - $31.01
Previous CloseN/A
Volume4.28M
Average Volume (3M)584.93K
Market Cap
$88.06M
Enterprise Value$191.73M
Total Cash (Recent Filing)$19.84M
Total Debt (Recent Filing)$1.62M
Price to Earnings (P/E)―
Beta2.66
Next Earnings
Mar 11, 2025EPS Estimate
-1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.75
Shares Outstanding15,001,353
10 Day Avg. Volume1,398,129
30 Day Avg. Volume584,929
Standard Deviation0.39
R-Squared0.09
Alpha-0.00739
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.58
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap2.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit21.30
Enterprise Value/Ebitda-2.85
Forecast
1Y Price Target
$62.78Price Target Upside969.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Jasper Therapeutics News
Bulls Say, Bears Say
Bulls Say
Dosing EfficacyBriq drove complete responses at all doses ≥80mg, with a single dose of 240mg briq resulting in CR=100% up to week 8, compared to 16.7% placebo.
Efficacy And Market DifferentiationThere is an opportunity for briquilimab to differentiate in the chronic urticaria market by offering a competitive efficacy profile, improved safety/tolerability, and a more convenient dosing regimen relative to its competition.
Safety And TolerabilityThe safety and tolerability of briquilimab were favorable with no serious adverse events noted, boding well for its use in mast cell diseases.
Bears Say
Comparative PerformanceThe stock is trading down based on briquilimab's value proposition versus barzolvolimab being less distinct.
Efficacy UncertaintyIt is still too early to determine briquilimab's efficacy differentiation given small patient numbers and that the go-forward dosing regimen is still not fully clear.
Safety ConcernsConcerns remain on the safety profile at 240mg specifically, as safety tables by dose level were not broken out, and the small sample size of n=3.
---
Ownership Overview
27.62% Insiders
9.56% Mutual Funds
0.02% Other Institutional Investors
54.62% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JSPR FAQ
What was Jasper Therapeutics, Inc.’s price range in the past 12 months?
Jasper Therapeutics, Inc. lowest stock price was $5.85 and its highest was $31.01 in the past 12 months.
What is Jasper Therapeutics, Inc.’s market cap?
Jasper Therapeutics, Inc.’s market cap is $88.06M.
When is Jasper Therapeutics, Inc.’s upcoming earnings report date?
Jasper Therapeutics, Inc.’s upcoming earnings report date is Mar 11, 2025 which is in 55 days.
How were Jasper Therapeutics, Inc.’s earnings last quarter?
Jasper Therapeutics, Inc. released its earnings results on Nov 07, 2024. The company reported -$1.24 earnings per share for the quarter, missing the consensus estimate of -$1.071 by -$0.169.
Is Jasper Therapeutics, Inc. overvalued?
According to Wall Street analysts Jasper Therapeutics, Inc.’s price is currently Undervalued.
Does Jasper Therapeutics, Inc. pay dividends?
Jasper Therapeutics, Inc. does not currently pay dividends.
What is Jasper Therapeutics, Inc.’s EPS estimate?
Jasper Therapeutics, Inc.’s EPS estimate is -1.26.
How many shares outstanding does Jasper Therapeutics, Inc. have?
Jasper Therapeutics, Inc. has 15,001,353 shares outstanding.
What happened to Jasper Therapeutics, Inc.’s price movement after its last earnings report?
Jasper Therapeutics, Inc. reported an EPS of -$1.24 in its last earnings report, missing expectations of -$1.071. Following the earnings report the stock price went down -4.262%.
Which hedge fund is a major shareholder of Jasper Therapeutics, Inc.?
Among the largest hedge funds holding Jasper Therapeutics, Inc.’s share is Woodline Partners LP. It holds Jasper Therapeutics, Inc.’s shares valued at 9M.
---
Jasper Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$62.78 (969.51% Upside)
$62.78 (969.51% Upside)
Blogger Sentiment
Bullish
JSPR Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 81.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 19.2%
Last 30 Days ▲ 19.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.03%
12-Months-Change
Fundamentals
Return on Equity
-75.92%
Trailing 12-Months
Asset Growth
-9.96%
Trailing 12-Months
Company Description
Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for blood and immune disorders. Headquartered in the vibrant life sciences hub of the San Francisco Bay Area, Jasper Therapeutics is pioneering the development of novel conditioning agents designed to safely prepare patients for hematopoietic stem cell transplantation. Their lead product candidate, JSP191, is a monoclonal antibody that aims to improve the outcomes and safety of stem cell transplants for conditions such as severe combined immunodeficiency (SCID) and acute myeloid leukemia (AML). The company operates within the biotechnology and pharmaceuticals sector, with a strong emphasis on advancing the field of regenerative medicine.
---
JSPR Stock 12 Month Forecast
Average Price Target
$62.78
▲(969.51% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Fate Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Best Analysts Covering JSPR
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-31.73%
reiterated a buy rating 8 days ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -31.73% per trade.
---